[Liver function studies under the influence of hormonal contraceptives (sequential preparations)].
20 fertile women who were treated with mestranol as oestrogen and both gestagenes chlormadinonacetate and norethisteronacetate were investigated. Alkaline phosphatase, ASAT, ALAT, alpha-amylase, cholesterol, bilirubin, serumproteins, indocyanine green half time, paper electrophoresis of serumproteins, thymol and zinc sulfate turbidity tests were examined during the first therapy cycle. Elevation of ALAT activity (6,3 I U/l to 12,14 u/l) was found during treatment with mestranol/chlormadinonacetate. A depression of ALAT (up to 5,34 u/l) was observed under additional therapy with gestagene chlormadinonacetate. Statistical significance was noted only for ALAT and alpha 1 globuline under sequential therapy with mestranol/norethisteronacetate.
D000293:Adolescent; D000328:Adult; D002715:Chlormadinone Acetate / Q000494:pharmacology; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000494:pharmacology*; D003279:Contraceptives, Oral, Sequential / Q000494:pharmacology*; D004338:Drug Combinations; D004341:Drug Evaluation; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008111:Liver Function Tests; D008656:Mestranol / Q000494:pharmacology; D009640:Norethindrone / Q000494:pharmacology
D003276:Contraceptives, Oral; D003279:Contraceptives, Oral, Sequential; D004338:Drug Combinations; D002715:Chlormadinone Acetate; D008656:Mestranol; D009640:Norethindrone
Leberfunktionsuntersuchungen unter dem Einfluss hormonaler Kontrazeptiva (Sequenzpräparate).